The CommonGround for Affordable Health Care Act (H.R.6575) amends the Internal Revenue Code and the Affordable Care Act to (1) extend and modify the temporary "enhanced" premium tax credit rules for the 2026 taxable year, including applying a revised percentage table and allowing eligibility up to 1,000% of the federal poverty level for that year; (2) add a package of fraud-prevention and consumer-protection rules governing agent- and broker-assisted enrollments in federally-run Exchanges, including new civil and criminal penalties, verification steps, audits, and requirements to remove deceased enrollees; (3) set a one-time extended open enrollment window for plan year 2026; and (4) impose substantial new transparency, contracting, audit, and remuneration constraints on pharmacy benefit managers (PBMs) operating in Medicare Part D and MA–PD markets, plus studies and reports to Congress.
Why it matters: the bill combines immediate consumer-facing changes (continued subsidy relief and a longer 2026 open enrollment) with heavy compliance and enforcement measures for intermediaries. Insurers, agents, PBMs, and Medicare plan sponsors would face new reporting, contracting, and potential liability exposures; HHS and oversight entities gain novel data and enforcement powers that will shape plan operations and the prescription-drug supply chain going forward.
At a Glance
What It Does
The bill extends the temporary enhanced premium tax credit mechanics into the 2026 taxable year with a new percentage table and raises the upper eligibility limit to 1000% of poverty for that year; it mandates enrollment-verification processes and stiff civil and criminal penalties for agents and brokers who submit incorrect or fraudulent Exchange enrollments; it requires quarterly Death Master File checks, expands audit and registration powers for agents/marketing organizations, and prescribes detailed PBM reporting and contracting rules for Part D and MA–PD sponsors.
Who It Affects
Directly affected parties include individual Marketplace enrollees receiving premium tax credits, agents and brokers and their field- or third‑party marketing partners, HHS-operated (federal) Exchanges, Medicare prescription drug plan sponsors and their PBMs, pharmacies (including affiliates), and state insurance regulators. PDP sponsors and MA–PD organizations must renegotiate PBM contracts to meet new disclosure and indemnity requirements.
Why It Matters
Operationally, the bill preserves consumer premium relief for 2026 while shifting enforcement upstream: it makes intermediary behavior (and the structure of PBM remuneration) a regulatory focus. That will change how commissions, lead generators, and PBMs are paid and audited, likely accelerating contractual revisions, data sharing demands, and state–federal oversight coordination.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Section 2 updates the IRS premium tax credit rules for the 2026 taxable year. Instead of ending the temporary enhanced subsidy schedule after 2025, the bill inserts a new short-term table and expressly suspends one of the statutory adjustment provisions, then extends eligibility for the credit through incomes up to 1,000% of the federal poverty level for taxable year 2026.
The change is narrowly framed as a one-year, tax-year-specific rewrite of percentage bands and applies to returns with taxable years beginning after December 31, 2025.
Section 3 is a multipart Exchange and agent/broker bill. It creates a separate civil-penalty tier applying to agents and brokers (negligent errors: $10,000–$50,000 per enrollee; knowing falsehoods: up to $200,000 per enrollee) and adds criminal penalties (up to 10 years) for willful fraud.
For Exchanges run by HHS the Secretary must implement a verification process for agent- or broker-submitted enrollments: agents must document consumer consent (for example, a standardized consent form), commissions may be withheld until eligibility inconsistencies are resolved, and agents must disclose chain‑of‑enrollment partners such as field marketing organizations and third‑party marketers. The bill also requires quarterly checks of the Social Security Death Master File to identify and remove deceased enrollees and mandates that Exchanges notify prospective enrollees of the size of any premium tax credit before enrollment (effective in 2027).The bill expands regulatory reach over field marketing organizations and third‑party marketers by authorizing HHS to set participation criteria—licensure, registration, marketing material review, termination reporting—and to require States to permit such oversight in their agent/broker approval processes.
HHS must run periodic audits, develop a suspended/terminated agent list, and coordinate referrals to state insurance departments. For federal Exchanges, the Secretary may terminate agent agreements on a preponderance-of-evidence standard.Section 4 directs HHS to set an extended open enrollment window for plan year 2026, moving the federally administered period to November 1, 2025 through March 19, 2026, and obliges outreach to inform eligible consumers.
Section 5 imposes new PBM rules in Medicare: PDP and MA–PD contracts must require PBMs and their affiliates to limit income to bona fide service fees (with narrowly defined exceptions), to pass through rebates or otherwise disclose and account for price concessions when passed to sponsors, to submit an extensive annual, machine‑readable report of drug‑level utilization, costs, rebates, affiliate activity, contract counter‑parties, and methods of calculation, and to accept sponsor audits. HHS gets authority to review remuneration arrangements for fair-market-value compliance; sponsors must disgorge improperly retained sums to HHS and obtain contractual remedies against PBMs.
The bill also funds OIG/CMS oversight work, orders a GAO study on price‑related compensation across the supply chain, and directs MedPAC to analyze PBM agreements. Finally, Section 6 sets a special fast‑track floor and committee process for any "enhanced premium tax credit reform bill" that meets the sponsor/cosponsor thresholds, with fixed deadlines for committee reporting and floor votes.
The Five Things You Need to Know
The bill rewrites the 36B premium percentage schedule just for the 2026 taxable year and temporarily allows eligibility for the enhanced premium tax credit up to 1,000 percent of the federal poverty level for that year only.
For negligent errors by agents or brokers in Exchange applications the bill creates a civil penalty range of $10,000–$50,000 per affected enrollee; for knowingly false or fraudulent submissions it authorizes civil penalties up to $200,000 per enrollee and criminal penalties up to 10 years imprisonment.
HHS-operated Exchanges must implement an agent/broker verification process that requires evidence of consumer consent, withholds broker commissions until enrollment inconsistencies are resolved, logs agent-of-record changes for consumer access, and requires reporting of field/third‑party marketing organizations involved in the chain of enrollment.
The PBM provisions require PDP sponsors and MA–PD plans to include contractual language ensuring PBMs limit remuneration to bona fide service fees (with strict definitions), to submit an annual July 1 machine-readable report containing per-drug utilization, rebate, and pricing data, and to submit to audits and disgorgement obligations.
The bill extends the open enrollment window for federally-run Exchanges for plan year 2026: November 1, 2025 through March 19, 2026, and requires outreach to notify qualified individuals of the extension.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
One-year extension and rewrite of enhanced premium tax credit mechanics
This section substitutes a new temporary percentage table into IRC section 36B for taxable year 2026 and explicitly suspends an adjustment clause for that year; it also swaps the statutory upper-income cap from 400% to 1,000% of FPL for 2026. Practically, that preserves a subsidy structure similar to pandemic-era enhancements but limited to a single tax year — important for tax filing, APTC calculations, and reconciliation risk for taxpayers and Exchanges.
Verification, penalties, audits, and consumer protections for agent-assisted enrollments
The bill expands section 1411 and 1311 protections by establishing a verification workflow in federally-run Exchanges: agents must capture evidence of consumer consent, disclose chain-of-enrollment participants, and commission payments can be delayed until inconsistencies identified by HHS are resolved. It creates a tiered civil-penalty scheme for agents and brokers (negligence vs. knowing fraud), adds criminal exposure for willful fraud, requires quarterly Death Master File checks to identify deceased enrollees, and authorizes HHS to audit, maintain a list of suspended/terminated agents, and refer cases to state insurance departments.
New federal criteria for field marketing organizations and third‑party marketers
HHS must issue criteria that states can use to decide whether to allow field marketing organizations and third‑party marketing organizations to participate in enrollments; criteria include standards of conduct (best‑interest duty), marketing review/approval, registration, licensure, prohibited misleading practices, and termination-reporting obligations. The specification of a ‘chain of enrollment’ and definitions for marketing and marketing materials signal that HHS intends to capture lead generators and outsourced sales funnels, not just licensed producers.
Extended open enrollment window for plan year 2026
This directs HHS to change the federal Exchange open enrollment rule for plan year 2026 to November 1, 2025–March 19, 2026 and requires outreach to qualified individuals. The extension is a discrete operational change with immediate downstream effects on plan administration, premium collection cycles, and agent/broker workflows.
Comprehensive PBM transparency, contracting, audit, and enforcement regime for Part D and MA–PD
The bill creates a dense compliance playbook for PBMs in Medicare markets: PDP sponsor contracts must require PBMs to limit remuneration to defined bona fide service fees (with narrowly defined exceptions for incentive payments and pass-through rebates), to provide annual, machine-readable, drug-level reports (utilization, wholesale acquisition cost, average pharmacy reimbursement, rebates retained by PBM/affiliates, affiliate dispensing shares, and more), to submit to sponsor audits, and to disgorge amounts retained in violation of the rules. HHS and OIG receive appropriations for oversight, GAO must study price-related compensation across the retail drug supply chain, and MedPAC must report on PBM agreements and trends.
Fast-track floor and committee procedures for future premium-credit reform bills
This procedural section defines an "enhanced premium tax credit reform bill" and prescribes accelerated committee reporting deadlines and nondebatable motions to proceed in both the House and Senate, with fixed final vote dates (no later than July 1, 2026). It is a House/Senate rules-style change enacted as statutory language to enforce expedited consideration of specified legislation meeting a bipartisan cosponsor threshold.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Low- and moderate-income Marketplace consumers (2026 tax year) — by preserving enhanced subsidy mechanics and broadening eligibility up to 1,000% FPL for that taxable year, reducing net premiums for many households filing 2026 returns.
- Consumers targeted by agent/broker fraud — the verification process, ability to see agent-of-record, timely notices of premium tax credit amounts, and quarterly Death Master File checks reduce unauthorized enrollments and make it easier to spot and reverse improper plan changes.
- Independent pharmacies and some plan enrollees — increased PBM transparency on reimbursement, affiliate dispensing, and pass-throughs may reveal differential treatment of pharmacy channels and could support more competitive contracting or policy remedies.
Who Bears the Cost
- Agents, brokers, field marketing organizations and third‑party marketers — face significant compliance obligations, registration, potential high civil fines ($10,000–$200,000 per enrollee), and criminal exposure for willful fraud, plus reputational risk from enhanced public listings and audits.
- PBMs and their affiliates — must restructure contracts to conform to bona fide fee limits, comply with complex annual disclosure and audit requests, and potentially disgorge retained revenue; smaller PBMs or vertically integrated entities may face heavy operational and legal costs.
- PDP sponsors and MA–PD organizations — must revise contracts to include indemnity/disgorgement language, manage PBM audits, process and secure voluminous machine-readable data, and may bear short-term administrative costs and sponsor-level reputational risk if PBM noncompliance triggers enforcement.
Key Issues
The Core Tension
The bill tries to square two conflicting priorities: protecting consumers and federal finances by aggressively policing intermediaries and forcing transparency, versus preserving broad, low‑friction access to subsidies and agent-assisted enrollment channels. Strong verification, stiff penalties, and PBM disclosure promote accountability and can reduce fraud and excessive retained revenue, but those same measures raise compliance costs, slow enrollment pathways, and risk concentrating market power among a smaller set of large vendors able to absorb reporting and audit burdens — a trade‑off with no easy administrative or policy resolution.
Implementation complexity and timing. The bill imposes extensive new data, audit, and contractual obligations on PBMs, sponsors, agents, and Exchanges with relatively short compliance lead times (notably for PBM machine‑readable reports and audit windows tied to 2028–2029).
HHS, OIG, and state regulators will need budgeting, staffing, and technical capacity to review high‑volume, commercially sensitive datasets and to run agent audits. The appropriations in the bill provide start‑up resources, but translating the statutory lists and definitions into interoperable reporting formats and secure data‑share mechanisms is a nontrivial operational lift.
Risk of enrollment frictions. The agent/broker verification flow (documenting consent, withholding commissions until inconsistencies are resolved, and adding registration/termination reporting) is targeted at fraud but will lengthen assisted enrollment workflows and could deter some agents and third‑party partners.
That can shrink assisted‑enrollment capacity for populations that rely on in‑person support and could shift enrollment to self‑service channels or brokers who migrate to state-regulated, non‑Exchange activity. There is also legal tension over evidentiary standards and due‑process: allowing termination of agent agreements by the Secretary on a preponderance‑of‑evidence basis lowers the standard for federal action compared with some state administrative processes, raising questions about appeals, confidentiality of investigatory materials, and coordination with state disciplinary regimes.
Commercial confidentiality vs. public accountability. PBM disclosure obligations are unusually granular—per‑drug claims counts, rebates retained, affiliate dispensing shares, and contract counterparty lists.
While intended to expose misaligned incentives, those data are often contract‑sensitive. The bill contains confidentiality limits but also permits selective disclosure to oversight entities; designing guards against re‑identification and protecting commercially valuable information while providing meaningful oversight will be contentious and technically demanding.
Finally, the bill permits pass‑through of rebates if fully passed to sponsors, but leaves many valuation and accounting questions (fair market value tests, treatment of aggregator fees, and inter‑affiliate transfers) to rulemaking and review, which creates litigation and negotiation risk between sponsors and PBMs during the transition.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.